BIODEXA PHARMACEUTICALS PLC

• ◆

  Material uncertainty over going concern

  The Directors believe there are adequate options and time available to secure additional financing for the Company and after considering the uncertainties, the Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements.

• ·

  Going-concern uncertainty disclosed

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

1. BIODEXA PHARMACEUTICALS PLC 2023-03-27 → present
2. MIDATECH PHARMA PLC 2014-11-27 → 2023-03-27
3. MIDATECH PHARMA LIMITED 2014-09-12 → 2014-11-27

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

PKF Littlejohn LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The Directors believe there are adequate options and time available to secure additional financing for the Company and after considering the uncertainties, the Directors consider it is appropriate to continue to adopt the going concern basis in preparing these financial statements.”

Group structure

1. BIODEXA PHARMACEUTICALS PLC · parent
   1. Biodexa Australia PTY Limited 100% · Australia · Trading company
   2. Biodexa Limited 100% · Cardiff, CF10 4DQ · Trading company
   3. Biodexa Ireland Limited 100% · Dublin 2, Ireland · Trading company
   4. Biodexa Pharmaceuticals (Wales) Limited 100% · Cardiff, CF10 4DQ · Trading company
   5. Biodexa US, Inc 100% · San Antonio, Texas · Trading company
   6. Haaland UK Limited 100% · Cardiff, CF10 4DQ · Dormant
   7. PharMida AG 100% · Basel, Switzerland · Dormant

Significant events

• “In December 2024 we issued an unsecured promissory note to C/M Capital Master Fund LP in the principal amount of $600,000 with a 10% original issue discount. The Note was an unsecured obligation with interest of 5% pa. and was fully repaid in December 2025.”
• “In January 2025, we entered into a three-year $35.0 million ELOC with C/M Capital Master Fund, LP. During calendar 2025 we used the ELOC to raise approximately $8.9 million in gross proceeds.”
• “In May 2025 we announced CPRIT had awarded an additional grant of $3.0 million, bringing the total to $20.0 million, to support the Phase 3 programme of eRapa in FAP.”
• “In December 2025 we closed a registered offering of ADSs and pre-funded warrants at $3.28 per ADS to raise gross proceeds of $10.0 million.”
• “On 4 February, 2026, the Company announced that it had entered into a license and collaboration agreement (the "License Agreement") with Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), pursuant to which Otsuka granted the Company an exclusive, worldwide (excluding Japan) license (the "Licensed Territory") to develop manufacture and commercialise OPB-171755, to be designated MTX240 ("MTX240").”
• “On 18 March 2026 the Company announced a change in the ratio of the Company's Ordinary Shares from each ADS representing 100,000 Ordinary Shares to each ADS representing 500,000 Ordinary Shares.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

14

last 12 months

Capital events

14

last 24 months

Officers appointed

2

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.